Cargando…
Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable. Despite recently approved novel targeted treatments such as lenalidomide and bortezomib, most MM patients' relapse is emphasizing the need for effective and well-tolerated therapies for this deadly disease. The...
Autores principales: | Thirukkumaran, Chandini M., Morris, Don G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199974/ https://www.ncbi.nlm.nih.gov/pubmed/22046569 http://dx.doi.org/10.1155/2011/632948 |
Ejemplares similares
-
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
por: Meyers, Daniel E., et al.
Publicado: (2017) -
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
por: Meyers, Daniel E., et al.
Publicado: (2017) -
Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
por: Marchica, Valentina, et al.
Publicado: (2021) -
Oncolytic virotherapy for pediatric malignancies: future prospects
por: Waters, Alicia M, et al.
Publicado: (2016) -
Review: Oncolytic virotherapy, updates and future directions
por: Fountzilas, Christos, et al.
Publicado: (2017)